Baxter/VimRx.
This article was originally published in The Gray Sheet
Executive Summary
Cell therapy joint venture, Nexell Therapeutics, will be headed by William McIntosh, former executive vice president of business development and chief financial officer at VimRx. Nexell, which formerly was Baxter's Immunotherapy Division, is developing and marketing cell therapies for cancer and other life-threatening diseases. The firm's lead products are the Isolex 300 and Isolex 300I cell selection systems. Although FDA's Biological Response Modifiers Advisory Committee did not take a formal vote on the Isolex 300's premarket approval application, the panel did agree that study data demonstrated efficacy ("The Gray Sheet" July 28, 1997, p. 8)...
You may also be interested in...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.